AMINO and Hufort agree on cooperation
AMINO and Hufort Healthcare Pvt. Ltd. have entered a new cooperation by signing a distribution and agency agreement …

Amino

Creating future

Amino acids are part of most metabolic processes of the human body. Therefore they are also essential components of numerous pharmaceutical and dietary products and clinical nutrition and contribute to restoring and preserving human health.

AMINO has been working for the efficiency and purity of these pharmaceutical substances. At our factory in Frellstedt, Germany we produce amino acids and other biological substances for customers all over the world.

News

13
08/
18
AMINO and Hufort agree on cooperation

AMINO and Hufort Healthcare Pvt. Ltd. have entered a new cooperation by signing a distribution and agency agreement.

>> more

AMINO and Hufort Healthcare Pvt. Ltd. have entered a new cooperation by signing a distribution and agency agreement.

Hufort, headquartered in Mumbay (India), specializes in the distribution and registration of active pharmaceutical ingredients. Hufort shall market, sell and distribute APIs manufactured by AMINO to Indian pharmaceutical customers.
“Working with Hufort Healthcare we allow us to access the Indian market, which holds an enormous potential for our company” says Dr. Shahid Iqbal Awan – the regional sales representative.

<< less
03
08/
18
AMINO considers strategic partnership for D-amino acids

The AMINO GmbH reviews a strategic partnership with MH2 Biochemical Co., Ltd (Korea).

>> more

The AMINO GmbH reviews a strategic partnership with MH2 Biochemical Co., Ltd (Korea).

The South Korean company, founded in 2003, is a manufacturer of biochemical products focusing on D-amino acids and supplying customers within the health and cosmetic sector. Through a cooperation with MH2 AMINO aims to expand its product offering in order to promote its international growth strategy. “First we have to carry out negotiations with MH2 to see how a cooperation between the two companies could work,” says Dr. Lutz, Thomas, CEO of AMINO.
“In any event we are interested in integrating new products and technologies into our range of products and services.”

<< less
26
07/
18
AMINO is awarded as innovative company

The AMINO GmbH was awarded by the German Stifterverband with the certificate “Innovative through Research” for its research and development activities.

>> more

The AMINO GmbH was awarded by the German Stifterverband with the certificate “Innovative through Research” for its research and development activities. The association collects regularly R & D data in order to identify the innovation power of German companies in order to develop appropriate development programs. “Our AminoVation-team develops new products and sustainable processes for the company.” explains Dr. Lutz Thomas, CEO of AMINO GmbH. “As an innovative company we are happy about the appreciation.”

<< less
>> Archive
20
07/
18
AMINO Korea Co. Ltd – the new subsidiary

AMINO GmbH announces that a new subsidiary was established under the name of Amino Korea Co., Ltd. 

>> mehr

AMINO GmbH announces that a new subsidiary was established under the name of Amino Korea Co., Ltd. The registration of Amino Korea was executed and authorized in Seoul as of July 4, 2018. "Through this subsidiary, we aim to expand our pharmaceutical-grade amino acids business in Asia by enhancing partnerships with customers and suppliers in a timely and sustainable manner to accelerate our international growth strategy" said Dr. Lutz Thomas, CEO of AMINO GmbH.

<< less
18
06/
18
Amino Acids successfully registered in the Ukraine

Together with its distribution partner IMCoPharma (Bílovec, Czech Republic) AMINO has successfully registered amino acids with the Ukrainian ministry for health.

>> mehr

Together with its distribution partner IMCoPharma (Bílovec, Czech Republic) AMINO has successfully registered amino acids with the Ukrainian ministry for health.

The registration in Kiev enables AMINO to sell the amino acids in the Ukraine for pharmaceutical applications.
Dr. Lutz Thomas, CEO of AMINO, is pleased about the successful registration of the products and states: “Our strategy involves the international expansion of our target markets and this marks a big step in the right direction. Furthermore this strengthens our relationship with IMCoPharma.”

<< less
16
03/
18
AMixCo Premix GmbH "stirs up" the Amino Acid Market!

AMINO is pleased to announce the foundation of AMixCo Premix GmbH dedicated to entering the market of amino acid premixes.

>> mehr

AMINO is pleased to announce the foundation of AMixCo Premix GmbH dedicated to entering the market of amino acid premixes.

As a manufacturer of premixes from active pharmaceutical or nutritional ingredients, AMixCo ensures the optimal composition of amino acids in various pharmaceutical and dietetic products.

Under the AMixCo brand amino acid premixes of a high quality and with a high reliability in tailor-made formulations will be offered. Customer-specific packaging and formulation are core competencies that form an integral part of the offer that AmixCo brings to its customers.

"The new positioning of AMixCo means an extension of our products and services repertoire for our customers and builds on the established market and production expertise of Amino GmbH to fulfill the specific requests of our customers," explains Project Manager Alexander Rath.


Please visit our homepage and contact us!

www.amixco.de/en

<< less
01
03/
18
AMINO Manufactures L-Histidine from Fermentation

AMINO offers L-histidine based on non-animal raw materials.

>> mehr

AMINO offers L-histidine based on non-animal raw materials.

The existing portfolio of fermentation products is consequently upgraded by L-histidine. “This addition to our product range steadily strengthens our business portfolio and we are just a few steps away from completing the range of amino acids from our own production“, comments Dr. Lutz Thomas, Managing Director of AMINO GmbH.

The semi-essential amino acid L-histidine possesses, thanks to the imidazole ring, aromatic properties whose central role in enzyme catalysis is of metabolic importance. As a component of hemoglobin L-histidine is responsible for the formation of red blood cells and therefore for the support of oxygen transport. In pharmaceutical applications, L-histidine is e.g. used as a component for infusion solutions. Because of L-histidine primarily having to be feed to infants, it is widely used in infant formula and in dietetic products.

<< less
22
02/
18
AMINO received Gold award from EcoVadis for sustainable business

AMINO received the Gold award and is therefore part of the top five percent of all companies rated by Eco Vadis.

>> mehr

AMINO received the Gold award and is therefore part of the top five percent of all companies rated by Eco Vadis.

EcoVadis is an independent platform for CSR reviews, on which companies can register the measures they take to implement corporate responsibility and have them reviewed.

“We are pleased with the positive recognition of our efforts to be sustainable and feel motivated and committed to improve further” says Kathrin Ebers, sustainability agent at AMINO GmbH, when asked about the company’s future goals.

<< less
08
01/
18
AMINO receives the CEP-Certificate for L-Tyrosine from Fermentation

AMINO has been granted the Certificate of Suitability (CEP) for the production of L-tyrosine from fermentation by the European Directorate for the Quality of Medicines (EDQM).

>> mehr

AMINO has been granted the Certificate of Suitability (CEP) for the production of L-tyrosine from fermentation by the European Directorate for the Quality of Medicines (EDQM).

AMINO is pleased that the certification of tyrosine derived from a fermentative manufacturing process expands the product portfolio of semi-essential amino acids. „The growth of our range for amino acids by tyrosine is an important step towards our growth plans” comments Dr. Lutz Thomas, Managing Director of AMINO GmbH.

With that authorization it is possible for AMINO, that focuses on the safe and effective production of pharmaceutical and nutritional substances, to expand the product portfolio at the amino acid market, especially for tyrosine and its derivatives.

<< less
14
06/
17
CEP for L-Arginine

AMINO has been granted the Certificate of Suitability (CEP) for the production of L-arginine by the European Directorate for the Quality of Medicines & HealthCare (EDQM).

>> mehr

AMINO has been granted the Certificate of Suitability (CEP) for the production of L-arginine by the European Directorate for the Quality of Medicines & HealthCare (EDQM).

“We are pleased to expand our portfolio for amino acids from fermentation for regulated pharmaceutical applications by receiving the CEP for L-arginine”, states Kai-Philipp Thomas, responsible for Regulatory Affairs at AMINO. “L-arginine, a semi-essential amino acid, is a mandatory component of pharmaceutical and specialty nutrition products and hence a strategically important addition to our product spectrum”, adds Dr. Lutz Thomas, Managing Director of AMINO GmbH.

<< less
02
06/
17
Expansion of CEP-Portfolio

AMINO has been granted a Certificate of Suitability (CEP) for the production of L-histidine by the European Directorate for the Quality of Medicines & HealthCare (EDQM).

>> mehr

AMINO has been granted a Certificate of Suitability (CEP) for the production of L-histidine by the European Directorate for the Quality of Medicines & HealthCare (EDQM).

“We are pleased to expand our portfolio for regulated pharmaceutical applications”, states Kai-Philipp Thomas, responsible for Regulatory Affairs at AMINO. “Histidine is one of the increasingly important amino acid of our broad product spectrum, hence we are very pleased that it is now CEP certified”, adds Dr. Lutz Thomas, Managing Director of AMINO GmbH.

L-histidine is a semi-essential amino acid and is used in many pharmaceutical products and infant formula.

<< less
31
03/
17
Expansion of Product Portfolio is proceeding

Amino has been granted the Certificate of Suitability (CEP) for the production of L-Lysine Acetate by the European Directorate for the Quality of Medicines & HealthCare (EDQM).

>> mehr

Amino has been granted the Certificate of Suitability (CEP) for the production of L-Lysine Acetate by the European Directorate for the Quality of Medicines & HealthCare (EDQM).

“We are pleased that we can now add the first amino acid salt to our product portfolio for regulated pharmaceutical applications.”, states Kai-Philipp Thomas, responsible for Regulatory Affairs at AMINO. “With this step we have succeeded the expansion of our product portfolio by amino acid derivatives.”, adds Michael Marx, Project Manager of the AMINOVATION-Team (www.aminovation.de).

L-Lysine is an essential amino acid, but is because of its poor stability as free base difficult to access for the human body. Therefore in many pharmaceutical and nutritional products the salts of L-lysine are used like L-lysine acetate. Due to the higher stability of L-lysine acetate the bioavailability of L-lysine rises.

<< less
17
03/
17
AMINO Receives CEP-Certificate for L-Valine

AMINO GmbH has been granted the Certificate of Suitability (CEP) for the production of L-Valine by the European Directorate for the Quality of Medicines & HealthCare (EDQM).

>> mehr

AMINO GmbH has been granted the Certificate of Suitability (CEP) for the production of L-Valine by the European Directorate for the Quality of Medicines & HealthCare (EDQM).

L-valine is an essential amino acid and is part of every important protein in the human body. Therefore L-valine is used in many pharmaceutical and nutritional products. “We are pleased to expand our product portfolio for regulated pharmaceutical applications by adding L-valine”, states Kai-Philipp Thomas, responsible for Regulatory Affairs at AMINO. “At the same time the certification by the EDQM reconfirms the first-class quality of our products.” “The CEP-certificate for L-valine is another step on our way towards completing the amino acid product range along with all globally relevant registrations and approvals”, adds Dr. Lutz Thomas, CEO of AMINO.

<< less
07
12/
16
AMINO Receives CEP-Certificate for L-Methionine

AMINO GmbH has been granted the Certificate of Suitability (CEP) for the production of L-methionine by the European Directorate for the Quality of Medicines (EDQM).

>> mehr

AMINO GmbH has been granted the Certificate of Suitability (CEP) for the production of L-methionine by the European Directorate for the Quality of Medicines (EDQM).

The sulfur-containing amino acid L-methionine plays an essential role in the human metabolism and is used in various pharmaceutical and nutraceutical products.

„Holding the CEP for L-methionine allows us to supply this essential amino acids to applications in regulated pharmaceutical products“, states Laura Schild, Marketing & Sales at AMINO. „AMINO’s L-methionine is derived from biotechnological processes. The fact that we can offer a sustainable alternative to the traditional chemico-enzymatically derived product to our customers is of particular significance “.

<< less
04
11/
16
Amino Receives CEP-Certificate for L-leucine from Fermentation

AMINO GmbH has been granted a Certificate of Suitability (CEP) by the European Directorate for the Quality of Medicines (EDQM) for the production of L-Leucine from fermentation.

>> mehr

AMINO GmbH has been granted a Certificate of Suitability (CEP) by the European Directorate for the Quality of Medicines (EDQM) for the production of L-Leucine from fermentation.

“AMINO has manufactured L-leucine for more than 35 years”, explains Dr. Sarah Schiefelbein responsible for Regulatory Affairs at AMINO. “With the receipt of the CEP certificate for L-leucine from fermentation, we can now offer this amino acid from a biotechnological process and have completed our L-leucine portfolio”.

<< less
23
09/
16
AMINO Sponsors LIONEL 2016

The LIONEL Design Award Braunschweig 2016 aims at emphasizing the relevance of design for the promotion of sales.

>> mehr

The LIONEL Design Award Braunschweig 2016 aims at emphasizing the relevance of design for the promotion of sales. This year’s focus of the award  was “Medical Design.” Creative heads from the areas of communication and design were asked to submit their artistic pieces of work in the field of medicine. AMINO gladly supported the special creativity of the participants with its sponsoring.

<< less
06
06/
16
AMINO Expands Production Capacity for L-Serine and DL-Serine

By optimizing the existing processes from fermentation and expanding the production capacity of pharma-grade products AMINO increases its production of L-serine and DL-serine.

>> mehr

By optimizing the existing processes from fermentation and expanding the production capacity of pharma-grade products AMINO increases its production of L-serine and DL-serine.

The high purity enantiomer L-serine as well as the racemic mixture DL-serine of the non-essential amino acid is used in various drug formulations as well as in products for clinical and special nutrition.

L- and DL-serine produced by AMINO meet pharmaceutical oral and infusion quality, comply with the requirements of international pharmacopoeias and are registered with the respective authorities.

In contrast to the widely-applied enzymatically catalyzed synthesis of serine from formaldehyde, AMINO’s serine is derived from modern biotechnological fermentation methods using microorganisms to produce the crude material from renewable resources. In addition to the application in the pharmaceutical and nutraceutical field, serine has high potential to be used as a platform chemical, representing the starting point for a range of chemical products.

<< less
11
05/
16
AMINO Publishes Sustainability Report

AMINO presents in the context of its internal policies its first sustainability report for the years 2013 - 2015.

>> mehr

AMINO presents in the context of its internal policies its first sustainability report for the years 2013 - 2015.

Sustainability is a key focus at AMINO, because our business is geared towards continuity. This principle is an integral part of our entrepreneurial mindset – with complete conviction and commitment, and of course in the best interest of our customers, who expect us to provide sustainable products and technologies that meet high environmental and social responsibility standards while being cost efficient at the same time.

In our first sustainability report, we would now like to describe how we meet these requirements and standards.

<< less
06
04/
16
AMINO Nominated for Foreign Trade Award of Lower Saxony 2016

AMINO is among the nominees for the Foreign Trade Award of the Federal State of Lower Saxony 2016 (Niedersächsischer Außenwirtschaftspreis 2016).

>> mehr

AMINO is among the nominees for the Foreign Trade Award of the Federal State of Lower Saxony 2016 (Niedersächsischer Außenwirtschaftspreis 2016). For several years the award is granted to businesses located in Lower Saxony to acknowledge outstanding performance in the field of foreign trade and exports.

“The mere nomination is a reward for AMINO’s success as a global supplier of high quality pharmaceutical amino acids and APIs to international markets“, says Dr. Lutz Thomas, Managing Director of AMINO.

„We would like to thank all our employess who made this nomination possible and deserve appreciation of their efforts“, adds Katja Thomas, Head of Human Resources at AMINO.

The award is presented on April 27th, 2016 during the 13th Foreign Trade Day (13. Außenwirtschaftstag) at the HANNOVER FAIR by the Minister for Economics, Labour and Transport, Mr. Olaf Lies.

<< less
29
03/
16
AMINO Starts Cooperation with IMCoPharma within the CIS Territory

AMINO has a new partner for the distribution of its high quality amino acids and related substances in the CIS region.

>> mehr

AMINO has a new partner for the distribution of its high quality amino acids and related substances in the CIS region. Therefore, AMINO entered a cooperation with the Czech company IMCoPharma that represents the basis for the distribution of AMINO´s products within the CIS territory by IMCoPharma.

IMCoPharma is a fully-serviced pharmaceutical company, headquartered in Bilovec (Czech Republic), with long-term experience within the CIS pharmaceutical market and a considerable cooperation network in the CIS countries Russia, Ukraine, Belarus, Uzbekistan, Kazakhstan, Turkmenistan, Moldova, Armenia, Georgia, Kyrgyzstan, Tajikistan and Azerbaijan.

The mission of IMCoPharma includes the creation and expansion of business relationships between the European and CIS pharmaceutical industry. Accordingly, the collaboration represents an important step for AMINO to reach new customers of this important market.

The goal of the collaboration is the development of a reliable and successful business relationship that optimizes the presentation and distribution of AMINO´s products within the CIS territory.

<< less
14
03/
16
AMINO Receives CEP-Certificate for Glycine

Amino GmbH has been granted a Certificate of Suitability (CEP) by the European Directorate for the Quality of Medicines (EDQM) for the production of glycine from chemical synthesis.

>> mehr

Amino GmbH has been granted a Certificate of Suitability (CEP) by the European Directorate for the Quality of Medicines (EDQM) for the production of glycine from chemical synthesis.

“The certification of glycine by the EDQM once more confirms the first-class quality of our products”, states Dr. Sarah Schiefelbein responsible for Regulatory Affairs at AMINO GmbH.” We are very pleased to add a new product to our portfolio targeted at quality sensitive nutritional and pharmaceutical applications.”

Amino produces pharmaceutical-grade glycine in its state-of-the-art facility in Frellstedt. Glycine is the smallest proteinogenic amino acid and an important component of almost all proteins and a crucial intermediate of the metabolism.

<< less
10
08/
15
AMINO Creates Space For More Efficiency

In the last weeks AMINO has demolished its former administration building in order to create additional space for the expansion of its production capacity.

>> mehr

In the last weeks AMINO has demolished its former administration building in order to create additional space for the expansion of its production capacity. It is intended to increase the production output of the plant immediately adjacent to the plot and specifically to supplement our technologies and processes.

Further restructuring of the facilities are scheduled targeted at compacting the premises and most importantly optimizing the material flows on site. In this context a new warehouse will be opened in fall of this year.

“We leave our past gradually behind us and develop the location further into a highly efficient site for pharmaceutical amino acids and APIs”, emphasizes Dr. Lutz Thomas, managing director of AMINOGmbH the company’s strategy. “Protection of resources and sustainability are major instruments for business success along with the acceptance of the challenges of the demographic shift”, adds Dr. Thomas. To this effect investments are planned for more efficiency.

<< less
23
07/
15
AMINO Determines its Carbon Footprint

Amino has in conjunction with its sustainability policy and in preparation of the sustainability report for the first time analyzed and determined its carbon footprint.

>> mehr

Amino has in conjunction with its sustainability policy and in preparation of the sustainability report for the first time analyzed and determined its carbon footprint.

The carbon footprint is an important monitoring and reporting instrument targeting the reduction and avoidance of CO2and greenhouse gas emissions. “We have decided to update and further research our carbon footprint annually in order to deduct recommendations for actions”, defines Kathrin Ebers, the responsible project leader, Amino’s commitment. “Sustainability with its three pillars economy, ecology and ethics is an integral cornerstone of our strategy for growth”, supports Dr. Lutz Thomas, managing director of Amino, the decision. We have scheduled the systems to be audited and certified according to DIN ISO 14064.

<< less
02
07/
15
AMINO Exhibits at Pharma ChemOutsourcing 2015

Amino is exhibiting at the Pharma ChemOutsourcing Conference and Exhibition taking place in Long Branch, NJ, USA on September 14-17, 2015.

>> mehr

Amino is exhibiting at the Pharma ChemOutsourcing Conference and Exhibition taking place in Long Branch, NJ, USA on September 14-17, 2015.

Being the largest USA-based API show, ChemOutsourcing attracts business development personnel from the pharmaceutical, biotech, chemical and chemistry service industries. We are looking forward to meeting buyers from the different industries and to present AMINO as a supplier of natural amino acids and related substances. AMINO will attend the show for the first time, specifically promoting the newly launched L-methionine as well as all other pharmaceutical grade amino acids.

Please visit AMINO at Pharma ChemOutsourcing 2015 at booth #30!

<< less
02
06/
15
AMINO Launches New L-Methionine

Amino GmbH today launched L-methionine amino acid as a safe and effective active pharmaceutical ingredient and nutritional substance.

>> mehr

Amino GmbH today launched L-methionine amino acid as a safe and effective active pharmaceutical ingredient and nutritional substance. Amino produces pharmaceutical-grade L-methionine in its state-of-the-art facility in Frellstedt, Germany, deriving the crude material from modern biotechnological methods, not through chemical synthesis. The entire L-methionine manufacturing process is free of animal-derived material, and does not use solvents at any point.

L-methionine is a sulfur-containing essential proteinogenic amino acid. The human body is not able to synthesize L-methionine by itself so has to be taken in in sufficient quantities from external sources. L-methionine plays a key role in many metabolic processes in the human body. Therefore it is an essential component of many pharmaceutical and nutraceutical products that contribute to restoring and preserving human health.

„The addition of L-methionine to our product range has allowed us to complete our portfolio of essential amino acids”, states Laura Schild, Marketing & Sales representative at AMINO. “We are specifically proud to offer L-methionine from fermentation and hence a sustainable alternative to the traditional products made from chemical processes”.

<< less
05
02/
15
CEP-Certificate for L-Alanine Granted!

Amino GmbH has been granted a Certificate of Suitability (CEP) by the European Directorate for the Quality of Medicines (EDQM) for the amino acid L-alanine as part of its strategic intent to supplement and complete the line of pharmaceutical-grade amino acid products.

>> mehr

Amino GmbH has been granted a Certificate of Suitability (CEP) by the European Directorate for the Quality of Medicines (EDQM) for the amino acid L-alanine as part of its strategic intent to supplement and complete the line of pharmaceutical-grade amino acid products.

„The CEP certificate provides the regulatory foundation for marketing of this non-essential amino acid in quality sensitive pharmaceutical applications“, states Stefanie Poppenhäger, Amino’s Director of Quality Management and Regulatory Affairs. „CEP applications for several other amino acids are under evaluation by EDQM or in the process development phase at Amino“, she adds. To a growing extent the amino acids manufactured by Amino are being registered outside of Europe. „We have reinforced our Regulatory Affairs division to assess the regulatory requirements in North and South America and in the Far East to allow the marketing of our products for pharmaceutical applications more efficiently“, emphasizes Dr. Lutz Thomas, Managing Director of Amino GmbH.

<< less
22
09/
14
Energy Management System according to DIN ISO 50001 Successfully Certified!

Amino has in the context of its sustainability program and specifically its energy policy committed to closely monitoring its electricity, gas and water – with a focus on cooling water – consumption and subsequently its reduction.

>> mehr

Amino has in the context of its sustainability program and specifically its energy policy committed to closely monitoring its electricity, gas and water – with a focus on cooling water – consumption and subsequently its reduction. An energy management system based on DIN ISO 50001:2011 was introduced and successfully certified.

“The preservation of resources and the increase of our profitability are fundamental motivations of Amino GmbH and we are pleased to align our entrepreneurial objectives with macroeconomic goals for the sake of the environment”, emphasizes Dr. Lutz Thomas, managing director of the company. “The continued growth of the past years is supplemented by a comprehensive strategy for the development of the site and its infrastructure amongst which the knowledge and management of the energy consuming processes are fundamental cornerstones”, adds Kathrin Ebers, Amino’s energy management appointee. “With the introduction of an energy management system according to DIN ISO 50001 we have given ourselves the framework to strengthen the awareness for energy consumption targeted at its sustainable reduction”.

<< less
22
09/
14
AMINO Receives CEP-Certificate for L-Tryptophan

Amino GmbH has been granted a Certificate of Suitability (CEP) by the European Directorate for the Quality of Medicines (EDQM) for the production of L-tryptophan from fermentation.

>> mehr

Amino GmbH has been granted a Certificate of Suitability (CEP) by the European Directorate for the Quality of Medicines (EDQM) for the production of L-tryptophan from fermentation.

L-tryptophan of fermentative origin is manufactured by Amino GmbH already since 2011. In conjunction with the GMP-certificate and the manufacturing permit for active pharmaceutical ingredients (APIs) of microbial origin according to §13 of the German Drug Act, the CEP-certificate facilitates the re-launch of L-tryptophan on the European pharmaceutical market and is hence an essential milestone to support the company’s strategic growth.

"The addition of L-tryptophan to our portfolio is an immediate result of our market orientation along with our strategic intent to supplement and complete the line of amino acids products", states Dr. Lutz Thomas, Managing Director of Amino GmbH “Amino will continue to strive for a full range of amino acids along with all relevant regulatory approvals and registrations targeted at quality sensitive nutritional and pharmaceutical applications” adds Stefanie Poppenhäger, Amino’s Director of Quality Management and Regulatory Affairs.

<< less
22
08/
14
AMINO Welcomes Matthew Guixé as Supply Chain Director

Amino GmbH is proud to announce the appointment of Mr. Matthew Guixé as Supply Chain Director.

>> mehr

Amino GmbH is proud to announce the appointment of Mr. Matthew Guixé as Supply Chain Director. Mr. Guixé is responsible for all aspects of the supply chain. “With the recruitment of Mr. Guixé we want to ensure the best possible coordination for all participants of the supply chain – starting with the supplier of raw materials to the customers of our finished products”, says Dr. Lutz Thomas, CEO of Amino GmbH.

In the last 2 years Mr. Guixé has worked as Supply Chain Manager for an English food manufacturer and was in charge of all aspects of supply chain operations including procurement, demand forecasting, production planning, warehousing and logistics.

“We are certain that Mr. Guixé is an excellent addition to the Amino team. Mr. Guixé reflects the international orientation of the company and our strategies”, emphasizes Dr. Lutz Thomas.

<< less
15
08/
14
AMINO Welcomes New Trainees!

On 1st August 2014 two young apprentices have began their training at Amino GmbH.

>> mehr

On 1st August 2014 two young apprentices have began their training at Amino GmbH.

Robin Rose will receive an education as industrial accountant and will experience the company's commercial departments.

Marvin Schmidt will be become an electronics technician in our site service team.

We wish them a good start, a succesful training - and especially:
have fun at work!

<< less
16
07/
14
AMINO Invests into Amino Acid Production Site in South Africa

As an integral part of its backward integration strategy Amino has founded a subsidiary in South Africa.

>> mehr

As an integral part of its backward integration strategy Amino has founded a subsidiary in South Africa. The company to be named Amino Manufacturing South Africa (Pty) Ltd. will be co-owned by Amino GmbH and two South African managers as minority shareholders. The scope of the new company encompasses the production and supply of crude amino acids to Amino and as a second step the manufacture of amino acids targeted at the nutrition market. “The investment marks a milestone in Amino’s history”, states Dr. Lutz Thomas, Amino’s managing director. “The new production site in Durban is our first investment outside of Europe and will form a significant cornerstone for our company moving forward”.

"We are excited to be involved in a venture with an international firm of the standing of Amino GmbH", said Ross Norton, MD of the new Amino (South Africa). "We expect that the benefit of the skills in South Africa and our favourable location and cost structure will enhance the business of our new parent company".

The production in South Africa will commence in quarter 1 of 2015.

<< less
20
05/
14
AMINO Re-Arranges Financing Structure for Growth

For years Amino GmbH has enjoyed above average growth and subsequently a growing demand for third party financing.

>> mehr

For years Amino GmbH has enjoyed above average growth and subsequently a growing demand for third party financing. “Our intention to continue the expansion of our business needed to be accompanied by investments into additional production capacity and utilities in Frellstedt and most importantly by growing challenges to finance the working capital implications of such growth”, explains Dr. Lutz Thomas, managing director of Amino GmbH. “The new syndicated loan that has been arranged for by Nord LB and Braunschweigische Landessparkasse and the new financial partners provides the foundation for additional growth and development in the coming years”, adds Norman Willatowski, Amino’s head of finances. Besides Nord LB the consortium is comprised of Sachsenbank, Volksbank Braunschweig – Wolfsburg and Kreissparkasse Peine. The loan facility and its medium to long-term structure is an advanced financial tool that is ideally suitable for the increasing requirements and business environment and scope of the company.

The next targets of the company’s development are the supplementation of the product portfolio and the construction of an additional production facility. “In the future we plan to manufacture up to five products in parallel”, describes Dr. Christian Pinkau, director of operations, the new challenge.

<< less
28
03/
14
New Products Added to GMP Certificate

The competent German authorities (Staatliches Gewerbeaufsichtsamt Braunschweig) have re-verified Amino’s GMP compliance following an extensive inspection of the manufacturing site in Frellstedt.

>> mehr


The competent German authorities (Staatliches Gewerbeaufsichtsamt Braunschweig) have re-verified Amino’s GMP compliance following an extensive inspection of the manufacturing site in Frellstedt.


The revised GMP certificate confirms observance of the EU Good Manufacturing Practice for Active Pharmaceutical Ingredients and approves new products such as L-tryptophan and L-asparagine monohydrate.


Amino will continue to strive for a full line of amino acids along with all relevant regulatory approvals and registrations targeted at quality sensitive nutritional and pharmaceutical applications. “The re-newed and expanded GMP certificate is an essential milestone to support the company’s strategic growth”, Stefanie Poppenhäger, Amino’s Director of Quality Management and Qualified Person, emphasizes the accomplishment.


“The confirmation of our GMP compliance of our site and specifically the expanded production capacity encourages Amino to invest into additional production capacity and production efficiency”, announces Dr. Lutz Thomas, the company’s managing director. “ We have already begun to hire and train additional personnel for the next projects and will launch new products from a new facility shortly”, he adds.

<< less
28
12/
13
API Marketing Authorization in Japan

AMINO GmbH has been granted a marketing authorization for the active pharmaceutical ingredient (API) Betaine Anhydrous by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) after confirmation of compliance with the current GMP guidelines.

>> mehr

AMINO GmbH has been granted a marketing authorization for the active pharmaceutical ingredient (API) Betaine Anhydrous by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) after confirmation of compliance with the current GMP guidelines. The plant in Frellstedt is accredited as manufacturing site by PMDA already since September 2013.

Betaine Anhydrous is distributed as API in Europe, USA and Canada. The recognition by the Japanese Pharmaceuticals and Medical Devices Agency allows AMINO access to the Japanese pharmaceutical market. Following the successful accreditation of the manufacturing site in Frellstedt, AMINO GmbH will obtain approval for its amino acids in Japan in 2014.

<< less
29
11/
13
Successful SMETA Certification

In October, Amino GmbH successfully passed the social SMETA-Audit which includes a detailed assessment of terms and conditions of safety, health, environmental, social and ethical standards.

>> mehr

In October, Amino GmbH successfully passed the social SMETA-Audit which includes a detailed assessment of terms and conditions of safety, health, environmental, social and ethical standards. Amino GmbH is proud to announce that the company meets all the compulsory criteria and can now officially be called SMETA-certified.   

Intention of the extensive SMETA-Audit (SEDEX Members Ethical Trading Audit), realized by two external auditors, was the inspection of the company’s compliance with all applicable national laws and guidelines as well as the ETI-Base Code (Ethical Trading Initiative). For that reason Amino GmbH provided a site inspection and an insight into the company’s procedures by allowing the auditors to have a close look at relevant papers and documents. Additionally, a high percentage of the employees were part of interviews in which the auditors received personal information on working conditions and atmosphere at Amino GmbH. 

“The SMETA-Certificate proofs that the first-class quality of our products is created and sustainably safeguarded under consideration of impeccable ethical and ecological conditions”, states Carina Patzelt, SHE Manager of Amino GmbH.        

Customers from all over the world can identify Amino GmbH on SEDEX (Supplier Ethical Data Exchange) as a company assuming its responsibility towards its employees, its customers and the environment.   

Dr. Lutz Thomas, managing director of Amino GmbH, emphasizes the importance of the certification especially with respect to the qualification as a supplier in the global nutrition market. “Ethical, ecologically sensitive and sustainable behavior is an important part of our business policy”, emphasizes Dr. Thomas.

<< less
23
10/
13
AMINO Participates in the Recruitment Fair for Apprentices in Helmstedt

With the intention to win good and motivated school graduates for the company, Amino participates in the recruitment fair in Helmstedt.

>> mehr

With the intention to win good and motivated school graduates for the company, Amino participates in the recruitment fair in Helmstedt. During which Amino presented training opportunities for three occupations. As a medium-sized company with firm bonds to the region. Amino requires well trained personnel for its continued growth. „It is logical to invest in the training of young people and future generations," says Katja Thomas, the Director of Human Resources. "With the active support of the current trainees and their experience in the communication via social networks, establishing contact is even more successful," Katja Thomas adds.

Amino currently seeks trainees for:

Industrial clerk male/female

You should interest in business processes and commercial activities. Even Microsoft Office knowledge is of advantage.

 

Industrial Mechanic at technician male/female

You should be interest in mechanic and possess a strong technical understanding.

 

Electronics technician male/female

You should enjoy self motivated work and have to be open for technical innovations.

<< less
15
03/
13
Inauguration of Plant 2

During a small celebration together with guests and employees Amino hands its third production line to its staff.

>> mehr

During a small celebration together with guests and employees Amino hands its third production line to its staff. Upon comprehensive reconstruction of plant 2 along with building production zones of different clean room levels the third production line will be utilized to manufacture amino acid 24 x 7. The annual production capacity amounts to 150 tons. With the intention to expand the range of products and services we have integrated a blender of the manufacture of amino acid premixes. Additional debottlenecking steps are scheduled to support further growth.

<< less
16
09/
12
AMINO Has Acquired All Remaining Plots and Lands

With effect of July 2nd, 2012 Amino GmbH and its shareholders have acquired all remaining plots of lands and buildings of the Frellsite site.

>> mehr

With effect of July 2nd, 2012 Amino GmbH and its shareholders have acquired all remaining plots of lands and buildings of the Frellsite site.

Center pieces of the acquisition and hence restructuring of the site are the centralized utility units and the membership in the waste water treatment plant in Süpplingenburg, plant 2 that will be refurbished and upgraded to be optimally suitable for small volume amino acids and amino acid blends, and storage facilities.

The storage facilities, i.e. the grain elevator business that has been acquired from Artus Lagerhaus Gesellschaft, Berlin, the molasses storage tanks and the former liquid sugar tanks have been acquired by and consolidated into the sister company AmStor GmbH. The storage business will be operated independent of the amino acids business.

Simultaneously the finished products warehouse with more than 1700 storage positions which are capable of holding approx. 260 t of amino acids has been put into operation.

The measures represent an important step towards the improvement of the efficiency of the site and a major milestone for the optimization of the material flow in Frellstedt.  

<< less
01
05/
11
AMINO and Danisco A/S Have Entered into a Cooperation Agreement Encompassing the Fermentation of Amino Acids

“The fermentation of amino acids at Danisco’s Grindsted location presents a major strategic move towards a backward integration of our supply chain”, states Dr. Lutz Thomas, managing director of Amino GmbH.

>> mehr

“The fermentation of amino acids at Danisco’s Grindsted location presents a major strategic move towards a backward integration of our supply chain”, states Dr. Lutz Thomas, managing director of Amino GmbH.

“We utilize the extensive fermentation know how of our partners in Grindsted and have secured significant fermentation capacity for the additional growth of our business”.

“For Danisco and its Grindsted location, the fermentation agreement that we have entered into with Amino GmbH is attractive as it pairs our set of capabilities in the field of biotechnology and fermentation along with a broad understanding of Good Manufacturing Practice for pharmaceuticals”, adds Martin K. Madsen, Site Manager in Grindsted. “We have invited Amino GmbH to our site as we believe that both parties will benefit from the synergies between ours and AMINO’s fermentation activities”.

The crude amino acids recovered in Grindsted will be transferred to Frellstedt for further processing to pharmaceutical-grade products. Initial product releases include L-isoleucine, L-serine and L-valine.

AMINO GmbH, headquartered in Frellstedt, Germany, is a fully integrated producer of specialty amino acids with natural biological origins. Restructured in November 2006, the company is dedicated to producing pharmaceutical-grade and infusion-grade amino acids under strict cGMP standards using the best extraction and purification technology (concentrating on vegetable raw materials) or state-of-the-art biotechnology/fermentation as appropriate.

<< less
08
04/
11
N-Acetyl-L-Tyrosine back in Product Portfolio

Motivated by customers´ inquiries AMINO GmbH expands its product line by offering N-acetyl-L-tyrosine in addition to L-tyrosine.

>> mehr

Motivated by customers´ inquiries AMINO GmbH expands its product line by offering N-acetyl-L-tyrosine in addition to L-tyrosine. “Amino acid derivatives represent the logical development and completion of our product range”, Dr. Lutz Thomas, Managing Director of AMINO GmbH, states. “This strategic move means an important step on our way of optimizing the services of Amino GmbH.”

AMINO GmbH, headquartered in Frellstedt, Germany, is a fully integrated producer of specialty amino acids with natural biological origins. Restructured in November 2006, the company is dedicated to producing pharmaceutical-grade and infusion-grade amino acids under strict cGMP standards using the best extraction and purification technology (concentrating on vegetable raw materials) or state-of-the-art biotechnology/fermentation as appropriate.

<< less
19
08/
10
AMINO Expands its Product Line

AMINO GmbH is proud to announce that L-aspartic acid, DL-aspartic acid and L-asparagine monohydrate have been added to the product line.

>> mehr

AMINO GmbH is proud to announce that L-aspartic acid, DL-aspartic acid and L-asparagine monohydrate have been added to the product line. These launches confirm AMINO’s intention to supplement its product range in order to offer an even larger variety of amino acids to its customers.

The product launches of L- and DL-aspartic acid as well as L-asparagine are the consequence of AMINO’s ongoing path of growth. “Intensive market monitoring has caused AMINO to expand its product line for the benefit of our customers”, states to Dr. Thomas, Managing Director of AMINO GmbH. The products are available as EP6/USP32-oral-grade as well as EP6/USP32- infusion-grade.

<< less
29
01/
10
AMINO Strengthens Management and Sales & Marketing Team

Since its restructuring AMINO GmbH has grown its business substantially.

>> mehr

Since its restructuring AMINO GmbH has grown its business substantially. In order to sustain its market international presence and to accelerate the development of the site in Frellstedt a step towards further expanding the skill base has been taken.

AMINO GmbH is proud to announce the recruitment of Mr. Norman Willatowski, MBA, as Operations Manager as of December 1st, 2009. Mr. Willatowski has worked six years as senior consultant for financing and project management at the consulting firm PricewaterhouseCoopers AG in Hanover and Berlin and was responsible for strategy consulting of medium-sized companies.

The marketing and sales team welcomes Mr. Uwe Koehler. Upon his successful graduation with a degree in business and management of Mr. Koehler has completed a trainee-program within the company. His key objectives are to closely work with customers targeting an expanded product line and range of services.

“With the reinforcement of our staff we are proactively adjusting to our developing business and setting the course for the strategic and operative development of our company for the benefit of our customers.” explains Dr. Lutz Thomas, managing director of AMINO GmbH.

<< less
06
02/
09
Second Production Line Fully Operational

With an investment of more than € 4 mn into a second GMP production line AMINO has in 2008 laid the groundwork for sustainable growth of the business.

>> mehr

With an investment of more than € 4 mn into a second GMP production line AMINO has in 2008 laid the groundwork for sustainable growth of the business.

The extension of the production and specifically the expansion of the evaporative crystallization for pharmaceutical amino acids results in a duplication of the annual production capacity. “This substantial investment sets the foundation for the growing product portfolio for pharmaceutical amino acids that AMINO offers”, explains the managing director Dr. Lutz Thomas. “Innovation and quick transfer into the production scale are the key success factors in the corporate strategy. We have over the past three years more than doubled the number of amino acids and will shortly launch further products to supplement our range”, adds Dr. Thomas.

AMINO GmbH, headquartered in Frellstedt, Germany, is a fully integrated producer of specialty amino acids with natural biological origins. The company is dedicated to producing pharmaceutical-grade and infusion-grade amino acids under strict cGMP standards using the best extraction and purification technology (concentrating on vegetable raw materials) or state-of-the-art biotechnology/fermentation as appropriate.

<< less
04
04/
08
AMINO Introduces L-Phenylalanine

AMINO GmbH adds L-phenylalanine to its product portfolio. L-phenylalanine is another essential amino acid offered by the company.

>> mehr

AMINO GmbH adds L-phenylalanine to its product portfolio. L-phenylalanine is another essential amino acid offered by the company.

Traditionally manufactured from extraction, the conversion towards L-phenylalanine from fermentation is an expression of change of technology promoted by AMINO. “We have been able to obtain a CEP certificate by the European Directorate for the Quality of Medicines (EDQM)”, explains Dr. Lutz Thomas, Managing Director of AMINO GmbH. “L-phenylalanine is offered in oral and pyrogen-free quality according to EP 6 and USP 30”, adds Stefanie Söchting, the company’s director for quality management.

<< less
03
03/
08
AMINO Expands Product Portfolio – CEP Certificate for L-Serine Granted

The expansion of Frellstedt plant’s production capacity for pharma-grade amino acids forms the backbone for the further enhancement for AMINO’s product offer.

>> mehr

The expansion of Frellstedt plant’s production capacity for pharma-grade amino acids forms the backbone for the further enhancement for AMINO’s product offer. By adding L-proline, DL-/L-aspartic acid and L-serine in pharma-oral and pyrogen-free quality AMINO broadens its range of products.

"The additional amino acids are an immediate result of our market orientation along with our strategic intent to supplement and complete the line of amino acids products", states Dr. Lutz Thomas, managing director of AMINO GmbH. In parallel AMINO accomplished another milestone. "The receipt of the CEP certificate for L-serine from fermentation marks another highlight in completing the regulatory support of the new products for our customers", agrees Stefanie Söchting, AMINO's director for regulatory affairs and quality management.

AMINO GmbH, headquartered in Frellstedt, Germany, is a fully integrated producer of specialty amino acids with natural biological origins. The company is dedicated to producing pharmaceutical-grade and infusion-grade amino acids under strict cGMP standards using the best extraction and purification technology (concentrating on vegetable raw materials) or state-of-the-art biotechnology/fermentation as appropriate.

<< less
23
11/
07
AMINO Invests in to Future

The AMINO GmbH is expanding its production capacity at its site in Frellstedt.

>> mehr

The AMINO GmbH is expanding its production capacity at its site in Frellstedt. The reinforcement of its production technology and the specifically the duplication of the annual output capacity primarily targeted at amino acids from fermentation are the focus of the plant expansion.

Core of the investment with a total volume of about 3 million € is the construction of a new production line beginning with a two-stage evaporation system and resulting in a modern pharmaceutical final products plant in supplementation to the GMP-certified plant concept.

"After the completed management buy-out and enthused by the successful GMP-certification for an API manufacturer under the German Drug Act, AMINO has decided to invest in the expansion and upgrading of its plants," says Dr. Lutz Thomas, the managing director of AMINO GmbH. “At the same time, these measures will create new jobs and sustain the profile of the AMINO GmbH regionally and in the international pharmaceutical industry”.

The strengthening of the business development team and the scheduled commissioning of the new facilities will enable AMINO to offer a large number of new amino acids and related substances in the short- and medium-term.

<< less
20
10/
07
New AMINO Homepage is Online

The launch of the new website of AMINO GmbH marks another milestone in the company endeavour to enforce its public appearance.

>> mehr

The launch of the new website of AMINO GmbH marks another milestone in the company endeavour to enforce its public appearance. Enhanced by the modern design the revised structure provides a quick and informative overview about the company and its products. Navigation within the site allows fast and dynamic access to information, e.g. it only takes a few clicks to download the specifications of AMINO’s products.

The new website is another building block in the restructuring of AMINO GmbH and is intended to endorse the company's actual innovation strength. With the newly-designed and user-friendly website, AMINO underlines its mission to be recognized as a modern and customer-oriented supplier of specialty amino acids.

<< less
17
07/
07
AMINO Forms New Business Development Team

Since its restructuring in late 2006, AMINO GmbH has taken a proactive, direct approach to generating customer contacts and thus strengthening its position in the marketplace.

>> mehr

Since its restructuring in late 2006, AMINO GmbH has taken a proactive, direct approach to generating customer contacts and thus strengthening its position in the marketplace. The response has been substantial, as evidenced by a large influx of projects to develop new products as well as new ways to make them.

To ensure the best management and fulfillment of these projects, AMINO has expanded its special Business Development team, integrating expert biotechnologists Annett Klinzing and Stefan Ortleb, as well as project manager Dr.-Ing. Holger Fersterra. The team will handle all aspects of the generation of new products and creation methods, managing projects from concept to final product.

<< less
14
05/
07
EDQM Grants AMINO Certificates of Suitability to Produce Infusion-Grade L-Isoleucine and L-Threonine

AMINO GmbH has been granted Certificates of Suitability (CEPs) by the European Directorate for the Quality of Medicines (EDQM) for the production of isoleucine and threonine via the company’s state-of-the-art fermentation process.

>> mehr

AMINO GmbH has been granted Certificates of Suitability (CEPs) by the European Directorate for the Quality of Medicines (EDQM) for the production of isoleucine and threonine via the company’s state-of-the-art fermentation process.

EDQM experts have judged AMINO’s manufacturing processes, including both fermentation and purification at its Frellstedt plant, to be GMP-compliant and suitable for constantly producing amino acids of infusion-grade quality. Isoleucine and threonine are the first amino acids produced via AMINO’s fermentation process to be accepted by the EDQM, notes Dr. Lutz Thomas, AMINO’s managing director, adding: “With these CEPs, AMINO can now place its fermentation-based isoleucine and threonine on the European infusion and pharmaceutical markets. Hence the CEPs mark a significant milestone in the company’s strategy.”

<< less
23
04/
07
AMINO Receives Permit to Produce Amino Acids from Fermentation

Following a comprehensive audit and inpection, AMINO GmbH has been granted a production permit according to §13 paragraph 1 of the German Drug Act by the regulatory authorities of Brunswick and Oldenburg.

>> mehr

Following a comprehensive audit and inpection, AMINO GmbH has been granted a production permit according to §13 paragraph 1 of the German Drug Act by the regulatory authorities of Brunswick and Oldenburg. With the implementation of the 14th amendment of the German Drug Act, manufacturers of active pharmaceutical ingredients (APIs) of microbial origin need a production permit issued by responsible authorities. AMINO GmbH produces amino acids from fermentation, which are considered APIs of microbial origin.

In addition, AMINO received a GMP certificate according to §64 paragraph 3 of the German Drug Act for its Frellstedt production facility and for the amino acids and other active substances manufactured there. The GMP certificate confirms the company’s adherence to the European GMP guidelines and compliance with the German Drug Act and the new drug and active substance manufacture directive (AMWHV).

<< less
22
11/
06
A New AMINO Emerges

A new AMINO has emerged with the completion of a leveraged management buyout of the amino acids business of AMINO GmbH.

>> mehr

A new AMINO has emerged with the completion of a leveraged management buyout of the amino acids business of AMINO GmbH. And now the company’s vision of becoming a leading supplier of specialty amino acids to the global marketplace is powered by the determination of its new management team.

Under the terms of the buyout, the new AMINO team, led by managing director Dr. Lutz Thomas and supported by new private investors, acquires the amino acids business together with the main assets of the former AMINO GmbH. These include its production site in Frellstedt and the jobs at this location, thus making the new AMINO one of the few amino acid manufacturers in Europe. In addition, the new company retains the AMINO name.The buyout followed several months of extensive negotiations, culminating in the decision in favor of the management-led restructuring aimed at maintaining the long-term strategy and unique position of AMINO in the amino acids marketplace, with its ability to supply the highest-quality products using the best extraction and purification technology or state-of-the-art fermentation technology as appropriate.

“We are back to focusing on our core business and more determined than ever before to become a leading supplier of specialty amino acids, thus bringing to reality the vision we began to develop through AmBio, a strategic alliance with our partners,” noted Dr. Thomas.

AMINO will focus completely on pharma- and infusion-grade amino acids produced under strict cGMP standards and developed from both extraction (concentrating on vegetable raw materials) technology and modern biotechnology/fermentation. The product line will include not only traditional products such as L-leucine, L-tyrosine, betaine pharma-grade (including betaine anhydrous, betaine HCI and betaine monohydrate), but also new amino acids from fermentation, including L-isoleucine, L-valine and L-threonine.

In addition, the company will launch L-serine and L-phenylalanine in early 2007. “It’s been a long time coming,” noted Dr. Thomas. “But AMINO is back. And we’ll be stronger than ever.”

<< less
<< Current

Brands of Amino: